The iCare HOME2 tonometer has demonstrated reliability for most eyes in clinical settings, according to a new study published in the Journal of Glaucoma.
The device, available to patients at Glaucoma Australia, is said to be a valuable adjunctive tool that patients and glaucoma suspects can use for easy and accurate IOP self-measurement to improve the ongoing management of glaucoma.
The restrospective study by Kratz et al., evaluated the accuracy, correlation, and analysis of differences in IOP measurements between the gold standard Goldmann applanation tonometer (GAT), and the iCare HOME2.
One hundred and thirty-five eyes of 70 patients were randomly selected. After a complete ocular examination, each patient’s IOP was measured and recorded with GAT and iCare HOME2. The mean IOP measured with iCare HOME2 was 16.5 ± 7.3 mmHg and GAT was 16.3 ± 6.5 mmHg.
The study found the instrument underestimated IOPs with corneas thinner than 522 µm, whereas it overestimated IOPs when corneas were thicker than this. As a result, researchers recommended central corneal thickness in patients who use iCare HOME2.
The ease-of-use and reliability of iCare HOME2 is said to assist with patient compliance with its gentle rebound technology and lack of anaesthesia or eye drops requirements that are associated with traditional tonometers.